[go: up one dir, main page]

WO2000011141A3 - Trna binding domain - Google Patents

Trna binding domain Download PDF

Info

Publication number
WO2000011141A3
WO2000011141A3 PCT/CA1999/000779 CA9900779W WO0011141A3 WO 2000011141 A3 WO2000011141 A3 WO 2000011141A3 CA 9900779 W CA9900779 W CA 9900779W WO 0011141 A3 WO0011141 A3 WO 0011141A3
Authority
WO
WIPO (PCT)
Prior art keywords
trna
loop
anticodon stem
interaction
determining whether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1999/000779
Other languages
French (fr)
Other versions
WO2000011141A2 (en
Inventor
Christopher Hogue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mt Sinai Hospital
Original Assignee
Mt Sinai Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mt Sinai Hospital filed Critical Mt Sinai Hospital
Priority to CA002341765A priority Critical patent/CA2341765A1/en
Priority to AU53671/99A priority patent/AU5367199A/en
Publication of WO2000011141A2 publication Critical patent/WO2000011141A2/en
Publication of WO2000011141A3 publication Critical patent/WO2000011141A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • C12Y601/01001—Tyrosine-tRNA ligase (6.1.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)

Abstract

There is disclosed a substantially pure peptide comprising the following sequence: [ML] -X(3) -[LIVMC] -X(3) -[GMNEHK] -[MLFYI] -X(2) -[ST] -X(3) -[SAIG] - [RMIK] -X(2) -[MIVA] -X(2) -[GNRHK] -X-[IVLF] -X-[LIV] -[NDSRGAL] -X(3) -[LIVSQ] -X(2) -[PILVTAC] wherein X represents any amino acid. Also disclosed is a method for determining whether a nucleic acid comprises a tRNA anticodon stem-loop. Another aspect comprises a method for identifying a substance which binds to a wherein the binding is detected by assaying for conjugates, for free substance, or for non-complexed peptide. Also described is a method of determining whether a test compound is an agonist or antagonist of a tRNA synthetase-tRNA anticodon stem-loop interaction or ribosomal S4 protein-tRNA anticodon stem-loop interaction. There is also described a method for obtaining a substantially pure nucleic acid comprising a tRNA anticodon stem-loop from a mixture of different nucleic acids. Finally, there is described a pharmaceutical composition for inhibiting the interaction of a tRNA, with a tRNA synthetase or ribosomal protein along with other related aspects.
PCT/CA1999/000779 1998-08-24 1999-08-24 tRNA BINDING DOMAIN Ceased WO2000011141A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002341765A CA2341765A1 (en) 1998-08-24 1999-08-24 Trna binding domain
AU53671/99A AU5367199A (en) 1998-08-24 1999-08-24 Trna binding domain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9767098P 1998-08-24 1998-08-24
US60/097,670 1998-08-24

Publications (2)

Publication Number Publication Date
WO2000011141A2 WO2000011141A2 (en) 2000-03-02
WO2000011141A3 true WO2000011141A3 (en) 2000-06-02

Family

ID=22264560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000779 Ceased WO2000011141A2 (en) 1998-08-24 1999-08-24 tRNA BINDING DOMAIN

Country Status (3)

Country Link
AU (1) AU5367199A (en)
CA (1) CA2341765A1 (en)
WO (1) WO2000011141A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033276A1 (en) * 1995-04-21 1996-10-24 Human Genome Sciences, Inc. NUCLEOTIDE SEQUENCE OF THE HAEMOPHILUS INFLUENZAE Rd GENOME, FRAGMENTS THEREOF, AND USES THEREOF
EP0785258A1 (en) * 1996-01-19 1997-07-23 Smithkline Beecham Plc Staphylococcus aureus tyrosyl-tRNA synthetase
WO1997039015A1 (en) * 1996-04-18 1997-10-23 Smithkline Beecham Corporation STREPTOCOCCUS PNEUMONIAE TYROSYL-tRNA SYNTHETASE
EP0841394A2 (en) * 1996-09-24 1998-05-13 Smithkline Beecham Corporation Staphylococcus aureus polynucleotides, polypeptides and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033276A1 (en) * 1995-04-21 1996-10-24 Human Genome Sciences, Inc. NUCLEOTIDE SEQUENCE OF THE HAEMOPHILUS INFLUENZAE Rd GENOME, FRAGMENTS THEREOF, AND USES THEREOF
EP0785258A1 (en) * 1996-01-19 1997-07-23 Smithkline Beecham Plc Staphylococcus aureus tyrosyl-tRNA synthetase
WO1997039015A1 (en) * 1996-04-18 1997-10-23 Smithkline Beecham Corporation STREPTOCOCCUS PNEUMONIAE TYROSYL-tRNA SYNTHETASE
EP0841394A2 (en) * 1996-09-24 1998-05-13 Smithkline Beecham Corporation Staphylococcus aureus polynucleotides, polypeptides and their uses

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 1 May 1991 (1991-05-01), HINXTON, GB, XP002133512 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 1 May 1992 (1992-05-01), HINXTON, GB, XP002133508 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 1 November 1995 (1995-11-01), HINXTON, GB, XP002133507 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 1 November 1995 (1995-11-01), HINXTON, GB, XP002133511 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 21 July 1986 (1986-07-21), HINXTON, GB, XP002133509 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 21 July 1986 (1986-07-21), HINXTON, GB, XP002133510 *
GRUNDY F J ET AL: "CLONING AND ANALYSIS OF THE BACILLUS SUBTILIS RPSD GENE, ENCODING RIBOSOMAL PROTEIN S4", JOURNAL OF BACTERIOLOGY,US,WASHINGTON, DC, vol. 172, no. 11, 1 November 1990 (1990-11-01), pages 6372 - 6379, XP000647921, ISSN: 0021-9193 *
HENKIN T M ET AL: "ANALYSIS OF THE BACILLUS SUBTILIS TYRS GENE: CONSERVATION OF A REGULATORY SEQUENCE IN MULTIPLE TRNA SYNTHETASE GENES", JOURNAL OF BACTERIOLOGY,US,WASHINGTON, DC, vol. 174, no. 4, 1 February 1992 (1992-02-01), pages 1299 - 1306, XP000647920, ISSN: 0021-9193 *
JARVEST R L ET AL: "Interaction of tyrosyl aryl dipeptides with S. aureus tyrosyl tRNA synthetase: inhibition and crystal structure of a complex", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 9, no. 19, 4 October 1999 (1999-10-04), pages 2859 - 2862, XP004179178, ISSN: 0960-894X *
JEANMOUGIN F ET AL: "Multiple sequence alignment with Clustal X", TIBS TRENDS IN BIOCHEMICAL SCIENCES,EN,ELSEVIER PUBLICATION, CAMBRIDGE, vol. 23, no. 10, 1 October 1998 (1998-10-01), pages 403 - 405, XP004146847, ISSN: 0968-0004 *
KORBER P. ET AL.,: "A new heat shock protein that binds nucleic acids", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 1, 1 January 1999 (1999-01-01), pages 249 - 256, XP002133513 *
KOZA J R: "AUTOMATED DISCOVERY OF DETECTORS AND ITERATION-PERFORMING CALCULATIONS TO RECOGNIZE PATTERNS IN PROTEIN SEQUENCES USING GENETIC PROGRAMMING", PROCEEDINGS OF THE COMPUTER SOCIETY CONFERENCE ON COMPUTER VISION AND PATTERN RECOGNITION,US,LOS ALAMITOS, IEEE COMP. SOC. PRESS, 1994, pages 684 - 689, XP000515914, ISBN: 0-8186-5827-4 *
NEUWALD A F ET AL: "DETECTING PATTERNS IN PROTEIN SEQUENCES", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 239, 1 January 1994 (1994-01-01), pages 698 - 712, XP000616986, ISSN: 0022-2836 *
PINTAR A ET AL.,: "Secondary structure of the C-terminal domain of the tyrosyl-transfer RNA synthetase from Bacillus stearothermophilus: a novel type of anticodon binding domain?", FEBS LETTERS, vol. 446, 1999, pages 81 - 85, XP000877454 *

Also Published As

Publication number Publication date
CA2341765A1 (en) 2000-03-02
AU5367199A (en) 2000-03-14
WO2000011141A2 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
Ganem et al. Detection of noncovalent receptor-ligand complexes by mass spectrometry
AU2001266894B2 (en) Selective labeling and isolation of phosphopeptides and applications to proteomeanalysis
JP3793124B2 (en) Rapid quantitative analysis of proteins or protein function in complex mixtures
US9023656B2 (en) Reactive mass labels
Dorrestein et al. Dissecting non-ribosomal and polyketide biosynthetic machineries using electrospray ionization Fourier-Transform mass spectrometry
Konno et al. Active site-directed proteomic probes for adenylation domains in nonribosomal peptide synthetases
US7884186B2 (en) Isotopically labeled trapping agent and method for identifying reactive metabolites
US20090068107A1 (en) Enzyme regulating ether lipid signaling pathways
Stein et al. Impact of epimerization domains on the intermodular transfer of enzyme‐bound intermediates in nonribosomal peptide synthesis
US20160223562A1 (en) Method for Determining the Concentration of a Peptide
WO2000011141A3 (en) Trna binding domain
NZ529986A (en) Protein characterisation by isolating a single C-terminal peptide from each polypeptide in a mixture with water-stable reagents that are selective for lysine followed by detection by mass spectroscopy
KR960705056A (en) IN VITRO ASSAY TO DETECT INHIBITORS OF PROTEIN AND / OR mRNA BIOSYNTHESIS
Sannes-Lowery et al. High throughput drug discovery with ESI-FTICR
Hicks et al. Fourier-transform mass spectrometry for detection of thioester-bound intermediates in unfractionated proteolytic mixtures of 80 and 191 kDa portions of Bacitracin A synthetase
US7537910B2 (en) Lactamase amplification substrate
EP0976734A3 (en) Selective inhibitors of viral or bacterial neuraminidase
Hilgenfeldt et al. Rat tissue kallikrein releases a kallidin‐like peptide from rat low‐molecular‐weight kininogen
AU2002358143A1 (en) Method for determining molecule-molecule interaction in proteomics
Seo et al. Mass-balanced 1H/2H isotope dipeptide tag for simultaneous protein quantitation and identification
EP2421883A1 (en) Trapping compounds and method for identifying reactive metabolites
Creese et al. The deimination of arginine to citrulline
Hollenhorst et al. The NRPS enzyme DdaD tethers Nβ-fumaramoyl-DAP for Fe (II)/α-ketoglutarate-dependent epoxidation by DdaC during dapdiamide antibiotic biosynthesis
AU2001277624A1 (en) Method for determining weather a test compound binds to a large rna target
Taj Aldeen Synthesis and Evaluation of Photoactivatable D-Amino Acid Probes of Bacterial Peptidoglycan Biosynthesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2341765

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2341765

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09762895

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase